RANBP9: A Potential Drug Target and Biomarker (G10048)

Target Name: RANBP9

NCBI ID: G10048

RANBP9

RANBP9: A Potential Drug Target and Biomarker

RanBP9 is a gene that encodes for a protein known as ranblanin. The ranblanin protein is a non-coding RNA molecule that has been shown to play a critical role in regulating gene expression and has been associated with various diseases, including cancer. In recent years, researchers have been investigating the potential drug targets and biomarkers associated with ranblanin, with a focus on RANBP9.

The RANBP9 gene was first identified in 2009 using DNA sequencing technology. The gene encodes a protein that has a molecular weight of approximately 19 kDa and a predicted localization to the endoplasmic reticulum (ER) and nuclear envelope (NE). The RANBP9 protein is composed of several functional domains, including a N-terminal transmembrane domain, a coiled-coil domain, and a C-terminal T-spine domain.

The N-terminal transmembrane domain of RANBP9 is known to be involved in the protein's cytoplasmic localization and functions as a receptor for various signaling molecules, including Wnt, FGF, and Shh. The coiled-coil domain of RANBP9 is responsible for the protein's stability and localization to the ER and NE. The C-terminal T-spine domain is known to be involved in protein-protein interactions and has been implicated in the regulation of cellular processes such as cell adhesion and migration.

Several studies have suggested that RANBP9 may be a potential drug target due to its involvement in various diseases. For example, RANBP9 has been shown to be overexpressed in various cancer types, including breast, ovarian, and colorectal cancers. Additionally, the RANBP9 gene has been associated with the development of neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease.

In addition to its potential clinical applications, RANBP9 has also been identified as a potential biomarker for various diseases. The RANBP9 protein has been shown to be expressed in various tissues and cells, including brain, spleen, and peripheral blood cells. Additionally, the RANBP9 gene has been shown to be expressed in various diseases, including cancer, neurodegenerative diseases, and autoimmune diseases.

In conclusion, RANBP9 is a gene that has been associated with various diseases and is potential drug target and biomarker. Further research is needed to fully understand the role of RANBP9 in disease progression and to develop effective treatments.

Protein Name: RAN Binding Protein 9

Functions: May act as scaffolding protein, and as adapter protein to couple membrane receptors to intracellular signaling pathways (Probable). Acts as a mediator of cell spreading and actin cytoskeleton rearrangement (PubMed:18710924). Core component of the CTLH E3 ubiquitin-protein ligase complex that selectively accepts ubiquitin from UBE2H and mediates ubiquitination and subsequent proteasomal degradation of the transcription factor HBP1 (PubMed:29911972). May be involved in signaling of ITGB2/LFA-1 and other integrins (PubMed:14722085). Enhances HGF-MET signaling by recruiting Sos and activating the Ras pathway (PubMed:12147692). Enhances dihydrotestosterone-induced transactivation activity of AR, as well as dexamethasone-induced transactivation activity of NR3C1, but not affect estrogen-induced transactivation (PubMed:12361945, PubMed:18222118). Stabilizes TP73 isoform Alpha, probably by inhibiting its ubiquitination, and increases its proapoptotic activity (PubMed:15558019). Inhibits the kinase activity of DYRK1A and DYRK1B. Inhibits FMR1 binding to RNA

The "RANBP9 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about RANBP9 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets